https://www.emdserono.com/us-en2026-01-14https://www.emdserono.com/us-en/company.html2026-02-24https://www.emdserono.com/us-en/company/who-we-are.html2025-01-31https://www.emdserono.com/us-en/company/who-we-are/global-organization.html2024-08-02https://www.emdserono.com/us-en/company/who-we-are/history.html2025-10-13https://www.emdserono.com/us-en/company/who-we-are/leadership-team.html2026-01-24https://www.emdserono.com/us-en/company/who-we-are/leadership-team/miguel-fernandez-alcalde.html2025-11-04https://www.emdserono.com/us-en/company/who-we-are/leadership-team/emily-ackerman.html2026-01-22https://www.emdserono.com/us-en/company/who-we-are/leadership-team/kate-cingolani.html2025-11-04https://www.emdserono.com/us-en/company/who-we-are/leadership-team/bob-dean.html2023-11-01https://www.emdserono.com/us-en/company/who-we-are/leadership-team/eduardo_fabiano.html2024-10-30https://www.emdserono.com/us-en/company/who-we-are/leadership-team/scott-holiday.html2026-01-22https://www.emdserono.com/us-en/company/who-we-are/leadership-team/libby-horne.html2026-01-17https://www.emdserono.com/us-en/company/who-we-are/leadership-team/vladimir-jeune.html2026-01-22https://www.emdserono.com/us-en/company/who-we-are/leadership-team/elaine-kang.html2026-01-22https://www.emdserono.com/us-en/company/who-we-are/leadership-team/michael-macdougall.html2026-03-18https://www.emdserono.com/us-en/company/who-we-are/leadership-team/tim-moore.html2026-01-24https://www.emdserono.com/us-en/company/who-we-are/leadership-team/andrea-mulford.html2026-01-22https://www.emdserono.com/us-en/company/who-we-are/leadership-team/melissa-reed.html2025-03-06https://www.emdserono.com/us-en/company/who-we-are/leadership-team/terri-stewart.html2024-10-30https://www.emdserono.com/us-en/company/who-we-are/leadership-team/john-struck.html2026-01-22https://www.emdserono.com/us-en/company/who-we-are/leadership-team/venkat-thiruvallur.html2026-01-17https://www.emdserono.com/us-en/company/who-we-are/leadership-team/dan-van-horn.html2026-01-22https://www.emdserono.com/us-en/company/who-we-are/leadership-team/joel-vandermeulen.html2024-10-22https://www.emdserono.com/us-en/company/who-we-are/leadership-team/lisa-walsh.html2024-10-30https://www.emdserono.com/us-en/company/vibrant-thoughts.html2026-02-17https://www.emdserono.com/us-en/company/vibrant-thoughts/cycling-inspiration-through-community-tim-golden.html2024-06-10https://www.emdserono.com/us-en/company/vibrant-thoughts/fathers-day.html2024-10-22https://www.emdserono.com/us-en/company/vibrant-thoughts/clinical-trials-wont-ever-be-the-same.html2023-06-01https://www.emdserono.com/us-en/company/vibrant-thoughts/covid-costs-on-workplace-equality.html2026-01-20https://www.emdserono.com/us-en/company/vibrant-thoughts/asrm-2021.html2024-10-22https://www.emdserono.com/us-en/company/vibrant-thoughts/kick-starting-2022.html2025-10-14https://www.emdserono.com/us-en/company/vibrant-thoughts/diversity-delivers.html2024-10-22https://www.emdserono.com/us-en/company/vibrant-thoughts/earth-day-2022.html2025-10-14https://www.emdserono.com/us-en/company/vibrant-thoughts/bladder-cancer-awareness-month-2022.html2024-03-27https://www.emdserono.com/us-en/company/vibrant-thoughts/family-building-tips-for-lgbtq-communities.html2026-03-30https://www.emdserono.com/us-en/company/vibrant-thoughts/finding-value-in-vbc.html2024-10-22https://www.emdserono.com/us-en/company/vibrant-thoughts/corporate-compliance-and-ethics-week.html2022-10-28https://www.emdserono.com/us-en/company/vibrant-thoughts/world-aids-day-2022.html2024-10-22https://www.emdserono.com/us-en/company/vibrant-thoughts/kickstarting-emd-serono-2023.html2025-10-14https://www.emdserono.com/us-en/company/vibrant-thoughts/community-matters-in-ms.html2024-10-22https://www.emdserono.com/us-en/company/vibrant-thoughts/head-neck-cancer-awareness-2023.html2024-10-22https://www.emdserono.com/us-en/company/vibrant-thoughts/military-appreciation-month-2023.html2024-10-22https://www.emdserono.com/us-en/company/vibrant-thoughts/patient-directed.html2023-07-18https://www.emdserono.com/us-en/company/vibrant-thoughts/back-to-school.html2025-09-08https://www.emdserono.com/us-en/company/vibrant-thoughts/national-family-caregivers-month-2023.html2023-11-09https://www.emdserono.com/us-en/company/vibrant-thoughts/emd-serono-headquarters-move-to-boston-seaport-district-2024.html2025-10-14https://www.emdserono.com/us-en/company/vibrant-thoughts/head-neck-cancer-awareness-2024.html2024-04-25https://www.emdserono.com/us-en/company/vibrant-thoughts/myasthenia-gravis.html2025-09-08https://www.emdserono.com/us-en/company/vibrant-thoughts/world-cancer-day-2025.html2025-01-30https://www.emdserono.com/us-en/company/vibrant-thoughts/patient-360-summit.html2025-07-17https://www.emdserono.com/us-en/company/contact-us.html2026-02-24https://www.emdserono.com/us-en/company/partnering.html2023-07-14https://www.emdserono.com/us-en/company/corporate_responsibility.html2025-10-13https://www.emdserono.com/us-en/company/corporate_responsibility/embracing_carers.html2025-10-15https://www.emdserono.com/us-en/company/corporate_responsibility/environmental_commitment.html2025-08-25https://www.emdserono.com/us-en/company/corporate_responsibility/patient-safety.html2025-08-26https://www.emdserono.com/us-en/company/corporate_responsibility/corporate-funding.html2026-01-14https://www.emdserono.com/us-en/company/news.html2025-08-28https://www.emdserono.com/us-en/company/news/press-releases.html2025-09-08https://www.emdserono.com/us-en/company/news/press-releases/new-mavenclad-4-year-data-highlighting-durable-effects.html2025-09-09https://www.emdserono.com/us-en/company/news/press-releases/china-accepts-marketing-authorization-pimicotinib-tgct-10-06-2025.html2025-10-16https://www.emdserono.com/us-en/company/news/press-releases/enpatoran-phase-2-data-cohort-b-11-06-2025.html2025-06-11https://www.emdserono.com/us-en/company/news/press-releases/phase-3-maneuver-pt-1-pimicotinib-data-28-05-2025.html2025-05-28https://www.emdserono.com/us-en/company/news/press-releases/asco-2025-22-05-2025.html2026-01-29https://www.emdserono.com/us-en/company/news/press-releases/enpatoran-phase-2-data-21-05-2025.html2025-06-05https://www.emdserono.com/us-en/company/news/press-releases/pimicotinib-option-exercise-27-03-2025.html2025-04-02https://www.emdserono.com/us-en/company/news/press-releases/miguel-fernandez-alcalde-to-lead-emd-serono-10-12-2024.html2025-11-04https://www.emdserono.com/us-en/company/news/press-releases/pimicotinib-topline-results-12-11-2024.html2024-11-22https://www.emdserono.com/us-en/company/news/press-releases/new-mavenclad-four-year-data-12-09-2024.html2025-05-12https://www.emdserono.com/us-en/company/news/press-releases/oral-cladribine-in-generalized-myasthenia-gravis-29-08-2024.html2024-09-06https://www.emdserono.com/us-en/company/news/press-releases/update-on-xevinapant-program-2024-highlights-24-06-2024.html2024-09-06https://www.emdserono.com/us-en/company/news/press-releases/oncology-update-03-06-2024.html2024-09-23https://www.emdserono.com/us-en/company/news/press-releases/asco-annual-meeting-2024-highlights-23-05-2024.html2025-03-08https://www.emdserono.com/us-en/company/news/press-releases/mavenclad-data-supports-cognitive-benefit-29-02-2024.html2024-02-29https://www.emdserono.com/us-en/company/news/press-releases/asco-gu-2024-highlights-22-01-2024.html2025-04-24https://www.emdserono.com/us-en/company/news/press-releases/merck-kgaa-expands-colorectal-cancer-portfolio-01-04-2024.html2025-04-24https://www.emdserono.com/us-en/company/news/press-releases/phase-3-result-update-for-evobrutinib-in-relapsing-ms-12-05-2023.html2024-01-19https://www.emdserono.com/us-en/company/news/press-releases/abbisko-commercialization-agreement-for-pimicotinib-04-12-2023.html2023-12-01https://www.emdserono.com/us-en/company/news/press-releases/plans-for-emd-serono-us-healthcare-headquarters-announced-14-11-2023.html2023-11-14https://www.emdserono.com/us-en/company/news/press-releases/2023-10-30-merck-kgaa-darmstadt-germany-strengthens-oncology-pipeline.html2024-09-23https://www.emdserono.com/us-en/company/news/press-releases/esmo-2023-highlights-16-10-2023.html2024-09-23https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-presents-evobrutinib-data-at-ectrims-actrims-11-10-2023.html2023-10-09https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-presents-mavenclad-data-at-ectrims-actrims-10-10-2023.html2023-10-09https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-launches-collaboration-with-un-guided-global-initiative-on-ageing-05-10-2023.html2023-10-09https://www.emdserono.com/us-en/company/news/press-releases/asco-2023-highlights-25-05-2023.html2024-09-23https://www.emdserono.com/us-en/company/news/press-releases/bavencio-merck-kgaa-darmstadt-germany-strengthens-oncology.html2023-03-27https://www.emdserono.com/us-en/company/news/press-releases/actrims-congress-23-02-2023.html2023-06-09https://www.emdserono.com/us-en/company/news/press-releases/new-analyses-reinforce-survival-benefit-of-bavencio-first-line-maintenance-treatment-in-patients-with-advanced-urothelial-carcinoma-13-02-2023.html2023-02-13https://www.emdserono.com/us-en/company/news/press-releases/adc-mersana-collaboration-22-12-2022.html2023-01-13https://www.emdserono.com/us-en/company/news/press-releases/research-and-development-update-call-21-11-2022.html2023-02-13https://www.emdserono.com/us-en/company/news/press-releases/evobrutinib-new-data-26-10-2022.html2022-11-28https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-showcases-ms-portfolio-at-ectrims-26-10-2022.html2022-11-28https://www.emdserono.com/us-en/company/news/press-releases/nerviano-collaboration-21-09-2022.html2022-11-28https://www.emdserono.com/us-en/company/news/press-releases/esmo-2022-xevinapant-five-year-data-07-09-2022.html2022-11-28https://www.emdserono.com/us-en/company/news/press-releases/esmo-2022-highlights-07-09-2022.html2022-11-28https://www.emdserono.com/us-en/company/news/press-releases/development-programs-in-oncology-04-06-2022.html2024-09-22https://www.emdserono.com/us-en/company/news/press-releases/asco-2022-highlights-26-05-2022.html2024-09-22https://www.emdserono.com/us-en/company/news/press-releases/advances-in-ms-portfolio-aan-2022-31-03-2022.html2024-01-17https://www.emdserono.com/us-en/company/news/press-releases/new-mavenclad-data-at-actrims-24-02-2022.html2022-11-10https://www.emdserono.com/us-en/company/news/press-releases/tepmetko-ec-approval-advanced-nsclc-18-02-2022.html2024-09-23https://www.emdserono.com/us-en/company/news/press-releases/bavencio-bladder-100-follow-up-ascogu-18-02-2022.html2022-11-10https://www.emdserono.com/us-en/company/news/press-releases/new-sustainable-slim-pack-for-fertility-medication-17-02-2022.html2022-11-10https://www.emdserono.com/us-en/company/news/press-releases/tepmetko-receives-positive-chmp-opinion-17-12-2021.html2024-09-22https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-launches-new-fertility-lifelines-tm-portal-29-11-2021.html2022-10-13https://www.emdserono.com/us-en/company/news/press-releases/new-data-show-dramatic-emotional-toll-of-pandemic-on-unpaid-caregivers-17-11-2021.html2024-09-22https://www.emdserono.com/us-en/company/news/press-releases/new-data-presented-at-ectrims-show-evobrutinib-14-10-2021.html2022-10-13https://www.emdserono.com/us-en/company/news/press-releases/new-real-world-mavenclad-data-presented-13-10-2021.html2022-10-13https://www.emdserono.com/us-en/company/news/press-releases/evobrutinik-ectrims-04-10-2021.html2022-10-13https://www.emdserono.com/us-en/company/news/press-releases/esmo-wclc-2021-highlights-13-09-2021.html2024-09-23https://www.emdserono.com/us-en/company/news/press-releases/asco-data-19-05-2021.html2024-09-23https://www.emdserono.com/us-en/company/news/press-releases/new-data-for-mavenclad-use-during-covid-19-pandemic-23-04-2021.html2022-11-07https://www.emdserono.com/us-en/company/news/press-releases/evobrutinib-is-first-and-only-btk-inhibitor-16-04-2021.html2022-11-07https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-advances-atr-inhibitor-berzosertib-in-small-cell-lung-cancer-12-04-2021.html2022-11-07https://www.emdserono.com/us-en/company/news/press-releases/topline-data-for-bintrafusp-alfa-as-second-line-monotherapy-treatment-in-biliary-tract-cancer-16-03-2021.html2022-11-07https://www.emdserono.com/us-en/company/news/press-releases/licensing-agreement-with-debiopharm-for-pivotal-stage-xevinapant-01-03-2021.html2022-11-07https://www.emdserono.com/us-en/company/news/press-releases/new-data-presented-at-actrims-forum-2021-indicate-mavenclad-treated-rms-patients-25-02-2021.html2022-11-07https://www.emdserono.com/us-en/company/news/press-releases/real-world-evidence-study-at-miami-cfar-suggests-hiv-associated-wasting-remains-an-underappreciated-comorbidity-09-02-2021.html2022-11-07https://www.emdserono.com/us-en/company/news/press-releases/merck-kgaa-darmstadt-germany-announces-leadership-change-for-north-america-04-02-2021.html2022-11-07https://www.emdserono.com/us-en/company/news/press-releases/fda-approves-tepmetko-for-patients-with-metastatic-nsclc-with-metex14-skipping-alterations-03-02-2021.html2022-12-16https://www.emdserono.com/us-en/company/news/press-releases/european-commission-approves-bavencio-r-avelumab-for-first-line-maintenance-treatment-02-01-2021.html2025-05-20https://www.emdserono.com/us-en/company/news/press-releases/merck-kgaa-darmstadt-germany-announces-update-on-the-intrpid-clinical-program-including-lung-037-study-20-10-2021.html2022-11-07https://www.emdserono.com/us-en/company/news/press-releases/bavencio-receives-positive-chmp-opinion-2020-12-11.html2024-01-16https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-embracing-carers-announces-study-results-covid19-and-caregive-2020-11-18.html2023-07-13https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-announces-retirement-of-dr-luciano-rossetti-2020-10-15.html2022-11-07https://www.emdserono.com/us-en/company/news/press-releases/bavencio-pivotal-phase-3-javelin-bladder-100-results-published-in-the-new-england-journal-of-medicine-18-09-2020.html2024-01-16https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-advances-oncology-portfolio-and-pipeline-with-new-and-long-term-data-in-multiple-cancers-at-esmo-13-09-2020.html2022-12-15https://www.emdserono.com/us-en/company/news/press-releases/positive-phase-2-results-for-investigational-sonelokinab-m1095-11-09-2020.html2022-11-17https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-to-showcase-new-data-at-actrims-ectrims-msvirtual2020-meeting-furthering-innovation-in-multiple-sclerosis-03-09-2020.html2022-11-17https://www.emdserono.com/us-en/company/news/press-releases/fda-accepts-filing-of-new-drug-application-for-tepotinib-25-08-2020.html2022-12-15https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-statement-on-rebif-contribution-to-us-niaid-for-actt-3-trial-05-08-2020.html2022-12-15https://www.emdserono.com/us-en/company/news/press-releases/fda-approves-bavencio-as-first-line-maintenance-treatment-for-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-30-06-2020.html2024-01-16https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-initiates-first-clinical-trial-of-tlr7-and-8-inhibitor-as-a-potential-treatment-for-severe-symptoms-of-covid-19-infection_25-06-2020.html2023-07-13https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-announces-launch-of-ms-in-the-21st-century-website-08-06-2020.html2022-12-15https://www.emdserono.com/us-en/company/news/press-releases/new-england-journal-of-medicine-publishes-primary-analysis-of-vision-data-for-tepotinib-in-advanced-nsclc-with-metex14-skipping-alterations-29-05-2020.html2022-12-15https://www.emdserono.com/us-en/company/news/press-releases/merck-kgaa-darmstadt-germany-and-twitch-join-forces-on-world-multiple-sclerosis-day-to-connect-people-living-with-ms-28-05-2020.html2024-01-16https://www.emdserono.com/us-en/company/news/press-releases/rebif-r-u-s-label-now-includes-pregnancy-outcomes-and-lactation-information-to-help-inform-treatment-decisions-for-women-with-ms-27-05-2020.html2024-10-08https://www.emdserono.com/us-en/company/news/press-releases/new-late-breaking-data-at-ean-indicate-evobrutinib-is-the-first-btk-inhibitor-to-report-efficacy-and-safety-in-ms-over-108-weeks-23-05-2020.html2022-12-15https://www.emdserono.com/us-en/company/news/press-releases/breakthrough-innovation-in-cancer-care-from-emd-serono-pipeline-to-be-presented-at-asco-13-05-2020.html2022-12-15https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-asco-2020showcase-significant-clinical-advances-in-cancer-care-30-04-2020.html2022-12-15https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-and-pfizer-receive-us-fda-breakthrough-for-bavenico-09-04-2020.html2024-01-16https://www.emdserono.com/us-en/company/news/press-releases/tepmetko-approved-in-japan-for-advanced-nsclc-with-metex14-skipping-alterations-25-03-2020.html2025-08-01https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-covid-19-response-19-03-2020.html2022-11-22https://www.emdserono.com/us-en/company/news/press-releases/merck-kgaa-statement-on-upcoming-updates-for-the-intrpid-lung-037-clinical-study-18-03-2020.html2022-12-15https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-and-pfizer-provide-update-on-phase-iii-javelin-head-and-neck-100-study-13-03-2020.html2024-01-16https://www.emdserono.com/us-en/company/news/press-releases/emd-serono-launches-family-planning-resource-center-with-myhealthteams-09-01-2020.html2022-12-15https://www.emdserono.com/us-en/company/news/press-releases/bavencio-significantly-improved-overall-survival-in-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-06-01-2020.html2024-01-16https://www.emdserono.com/us-en/company/news/press-releases/agreement-with-u-s-government-to-expand-access-to-ivf-therapies-16-10-2025.html2025-11-04https://www.emdserono.com/us-en/company/news/press-releases/pimicotinib-maneuver-longer-term-results-esmo-2025-17-10-2025.html2025-10-16https://www.emdserono.com/us-en/company/news/press-releases/fda-grants-fast-track-designation-cladribine-for-gmg-24-11-2025.html2025-11-21https://www.emdserono.com/us-en/company/news/press-releases/pimicotinib-approved-for-tgct-in-china-22-12-2025.html2025-12-22https://www.emdserono.com/us-en/company/news/press-releases/fda-accepts-new-drug-application-for-pimicotinib-12-01-2026.html2026-01-12https://www.emdserono.com/us-en/company/news/press-releases/advanced-patient-access-to-ivf-medicines-in-the-us-06-02-2026.html2026-02-05https://www.emdserono.com/us-en/company/news/media-library.html2023-01-18https://www.emdserono.com/us-en/company/news/media-library/sites-and-buildings/emd-serono-billerica-logo-on-building.html2022-11-16https://www.emdserono.com/us-en/company/news/media-library/sites-and-buildings/emd-serono-billerica-aerial-view.html2022-11-16https://www.emdserono.com/us-en/company/news/media-library/sites-and-buildings/emd-serono-billerica-cafeteria-booths.html2022-11-16https://www.emdserono.com/us-en/company/news/media-library/sites-and-buildings/emd-serono-billerica-cafeteria.html2022-11-16https://www.emdserono.com/us-en/company/news/media-library/sites-and-buildings/emd-serono-billerica-laboratory.html2022-11-16https://www.emdserono.com/us-en/company/news/media-library/sites-and-buildings/emd-serono-billerica-sculpture.html2022-11-16https://www.emdserono.com/us-en/company/news/media-library/sites-and-buildings/emd-serono-boston-vibrant-m.html2025-10-13https://www.emdserono.com/us-en/company/news/media-library/logos/media-gallery-logo-emd-serono-red.html2023-01-19https://www.emdserono.com/us-en/company/news/media-library/logos/media-gallery-logo-emd-serono-cyan.html2022-11-07https://www.emdserono.com/us-en/company/news/media-library/logos/media-gallery-logo-emd-serono-cyan1.html2022-11-07https://www.emdserono.com/us-en/company/news/media-library/b-roll/emd-serono-billerica-b-roll-footage.html2022-12-16https://www.emdserono.com/us-en/company/news/media-library/b-roll/emd-serono-corporate-b-roll-footage.html2025-10-16https://www.emdserono.com/us-en/company/news/press-release-archive.html2024-01-12https://www.emdserono.com/us-en/company/news/press-release-subscription.html2024-04-30https://www.emdserono.com/us-en/expertise.html2026-02-24https://www.emdserono.com/us-en/expertise/healthcare-professionals.html2024-12-10https://www.emdserono.com/us-en/expertise/neurology-and-immunology.html2025-12-10https://www.emdserono.com/us-en/expertise/endocrinology.html2026-02-24https://www.emdserono.com/us-en/expertise/fertility.html2026-02-24https://www.emdserono.com/us-en/expertise/oncology.html2026-01-21https://www.emdserono.com/us-en/research.html2025-12-20https://www.emdserono.com/us-en/research/diversity-inclusion-clinical-trials.html2025-11-21https://www.emdserono.com/us-en/careers.html2024-04-30https://www.emdserono.com/us-en/patients-and-caregivers.html2025-10-16https://www.emdserono.com/us-en/patients-and-caregivers/get-help-paying-for-your-medication.html2026-02-24https://www.emdserono.com/us-en/patients-and-caregivers/how-is-emd-serono-patient-directed.html2025-10-16https://www.emdserono.com/us-en/patients-and-caregivers/patient-directed-initiatives.html2024-04-02https://www.emdserono.com/us-en/compliance-transparency.html2026-01-20https://www.emdserono.com/us-en/privacy-policy/hcp-privacy-notice.html2023-01-26https://www.emdserono.com/us-en/locations/country-usa-emd-serono-r-and-d-hub-boston.html2018-09-14https://www.emdserono.com/us-en/sitemap.html2026-02-24